PBMCs and SN of PBMCs Induce Cell Cycle Arrest of ECs in G0/1 Independent of Any Preactivation
| Treatment . | % of Cells* (±SD) in . | ||
|---|---|---|---|
| . | G0/1-Phase . | S-Phase . | G2-Phase . |
| EC | 68 (±11.8) | 22.5 (±11.6) | 7.5 (±2.4) |
| EC+SN-PBMC | 82 (±4.9) | 3 (±2.4)† | 12.3 (±4.3) |
| EC+SN-PBMC-IR | 78.3 (±4.2) | 5 (±3)† | 14 (±4.3) |
| EC+PBMC | 81.3 (±1.2) | 6 (±2.6)† | 10.7 (±1.5) |
| EC+PBMC-IR | 81 (±5) | 4.7 (±2.1)† | 11 (±5.3) |
| Treatment . | % of Cells* (±SD) in . | ||
|---|---|---|---|
| . | G0/1-Phase . | S-Phase . | G2-Phase . |
| EC | 68 (±11.8) | 22.5 (±11.6) | 7.5 (±2.4) |
| EC+SN-PBMC | 82 (±4.9) | 3 (±2.4)† | 12.3 (±4.3) |
| EC+SN-PBMC-IR | 78.3 (±4.2) | 5 (±3)† | 14 (±4.3) |
| EC+PBMC | 81.3 (±1.2) | 6 (±2.6)† | 10.7 (±1.5) |
| EC+PBMC-IR | 81 (±5) | 4.7 (±2.1)† | 11 (±5.3) |
Cell-cycle analysis was performed as described in the Materials and Methods. Results are given as the percentage of cells in the respective cell cycle phase (±SD).
Mean of at least three experiments.
P < .05 of BrdU+ (S-phase) control ECs versus BrdU+ ECs after incubation with (SN−) PBMCs treated as given.